EY, the embattled audit giant, has re-entered the Dax-listed audit sphere by securing Qiagen, a biotech heavyweight, as its new auditor. This surprising comeback follows a two-year ban on acquiring listed clients in Germany due to the Wirecard scandal, where EY’s audits faced allegations of gross negligence.